DECLARE-TIMI 58 HF Risk Reduction Score Calculator
Patient profile
Complete all fields using the stated units.
Clinical context
DECLARE–TIMI 58 evaluated dapagliflozin versus placebo in people with type 2 diabetes who had or were at risk for atherosclerotic cardiovascular disease. The trial reported a reduction in the composite of cardiovascular death or hospitalization for heart failure, driven by fewer hospitalizations for heart failure.
This page preserves the original code's input variables, point assignments, and score cutoffs for transparency, but labels the result as a simplified educational score. It does not calculate a validated absolute event probability, number needed to treat, or individual treatment benefit.
Scoring rules in the supplied source code
| Variable | Original rule | Points |
|---|---|---|
| Age | ≥75 years / 65–74 years | +2 / +1 |
| History of HF | Yes | +3 |
| Established ASCVD | Yes | +1 |
| eGFR | <60 / 60–89 mL/min/1.73 m² | +2 / +1 |
| Albuminuria | UACR ≥30 mg/g | +2 |
| HbA1c | ≥8% | +1 |
| Sex | Male | +0.5 |
Original code's categories: score ≥7, high; score ≥4 and <7, moderate; score <4, low. These are code-defined categories, not validated clinical risk strata.
References
Clinical notes
Document key findings and keep a structured record for your own reference.
My notes
Review, edit, or remove notes saved in this browser.
Report an issue
Your feedback helps us improve the reliability and usability of this clinical tool.